{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:39:39Z","timestamp":1776335979555,"version":"3.51.2"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Key Clinical Specialty Construction Project"},{"name":"Guangxi Medical And Health Key Discipline Construction Project"},{"name":"Guangxi Key Clinical Specialty Construction Project"},{"name":"Natural Science Youth Fund of Guangxi Zhuang Autonomous Region","award":["2022GXNSFBA035497"],"award-info":[{"award-number":["2022GXNSFBA035497"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiothorac Surg"],"DOI":"10.1186\/s13019-026-03912-5","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T02:05:36Z","timestamp":1773108336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a nomogram using transaminase levels, cycle cost, and hair loss as predictive factors for the response to neoadjuvant chemotherapy in esophageal cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Shu-Cong","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun-Lin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-Fu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shang-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"3912_CR1","doi-asserted-by":"crossref","unstructured":"Harada K et al. Recent advances in treating oesophageal cancer. F1000Res, 2020. 9.","DOI":"10.12688\/f1000research.22926.1"},{"issue":"3","key":"3912_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 33","key":"3912_CR3","doi-asserted-by":"publisher","first-page":"S4162","DOI":"10.21037\/jtd.2018.10.39","volume":"10","author":"T Lerut","year":"2018","unstructured":"Lerut T. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus: the (NEOCRTEC5010) trial-a timely and welcome clinical trial from the Far East. J Thorac Dis. 2018;10(Suppl 33):S4162\u20134.","journal-title":"J Thorac Dis"},{"issue":"7","key":"3912_CR4","doi-asserted-by":"publisher","first-page":"855","DOI":"10.6004\/jnccn.2019.0033","volume":"17","author":"JA Ajani","year":"2019","unstructured":"Ajani JA, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(7):855\u201383.","journal-title":"J Natl Compr Canc Netw"},{"issue":"18","key":"3912_CR5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.20.03614","volume":"39","author":"BM Eyck","year":"2021","unstructured":"Eyck BM, et al. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. J Clin Oncol. 2021;39(18):1995\u20132004.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3912_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/01.JAA.0001007328.84376.da","volume":"37","author":"DC Eisner","year":"2024","unstructured":"Eisner DC. Esophageal cancer: Treatment advances and need for screening. Jaapa. 2024;37(4):19\u201324.","journal-title":"Jaapa"},{"issue":"13","key":"3912_CR7","first-page":"1381","volume":"50","author":"T Konishi","year":"2023","unstructured":"Konishi T, et al. [Safety and Efficacy of Neoadjuvant Chemotherapy(UDON: 5-FU, Docetaxel, and Nedaplatin)for Esophageal Cancer]. Gan Kagaku Ryoho. 2023;50(13):1381\u20133.","journal-title":"Gan Kagaku Ryoho"},{"issue":"4","key":"3912_CR8","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/cas.15703","volume":"114","author":"H Furuke","year":"2023","unstructured":"Furuke H, et al. Plasma microRNA-192-5p can predict the response to neoadjuvant chemotherapy and prognosis in esophageal cancer. Cancer Sci. 2023;114(4):1686\u201396.","journal-title":"Cancer Sci"},{"issue":"8","key":"3912_CR9","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1007\/s00261-023-03938-6","volume":"48","author":"S Oda","year":"2023","unstructured":"Oda S, et al. Computed tomography-based radiomic analysis for predicting pathological response and prognosis after neoadjuvant chemotherapy in patients with locally advanced esophageal cancer. Abdom Radiol (NY). 2023;48(8):2503\u201313.","journal-title":"Abdom Radiol (NY)"},{"issue":"12","key":"3912_CR10","doi-asserted-by":"publisher","first-page":"7185","DOI":"10.1245\/s10434-021-10025-x","volume":"28","author":"T Ishida","year":"2021","unstructured":"Ishida T, et al. Quantity and Quality of Skeletal Muscle as an Important Predictor of Clinical Outcomes in Patients with Esophageal Cancer Undergoing Esophagectomy after Neoadjuvant Chemotherapy. Ann Surg Oncol. 2021;28(12):7185\u201395.","journal-title":"Ann Surg Oncol"},{"issue":"28","key":"3912_CR11","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.1200\/JCO.23.00139","volume":"41","author":"JL Moore","year":"2023","unstructured":"Moore JL, et al. Pathologic Lymph Node Regression After Neoadjuvant Chemotherapy Predicts Recurrence and Survival in Esophageal Adenocarcinoma: A Multicenter Study in the United Kingdom. J Clin Oncol. 2023;41(28):4522\u201334.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3912_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jtho.2016.10.016","volume":"12","author":"TW Rice","year":"2017","unstructured":"Rice TW, et al. Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer. J Thorac Oncol. 2017;12(1):36\u201342.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"3912_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"key":"3912_CR14","doi-asserted-by":"publisher","first-page":"1051841","DOI":"10.3389\/fimmu.2022.1051841","volume":"13","author":"Q Li","year":"2022","unstructured":"Li Q, Liu T, Ding Z. Neoadjuvant immunotherapy for resectable esophageal cancer: A review. Front Immunol. 2022;13:1051841.","journal-title":"Front Immunol"},{"issue":"2","key":"3912_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.annonc.2022.10.508","volume":"34","author":"H Tang","year":"2023","unstructured":"Tang H, et al. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial. Ann Oncol. 2023;34(2):163\u201372.","journal-title":"Ann Oncol"},{"issue":"3","key":"3912_CR16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10388-022-00980-z","volume":"20","author":"S Matsuda","year":"2023","unstructured":"Matsuda S, et al. Old age and intense chemotherapy exacerbate negative prognostic impact of postoperative complication on survival in patients with esophageal cancer who received neoadjuvant therapy: a nationwide study from 85 Japanese esophageal centers. Esophagus. 2023;20(3):445\u201354.","journal-title":"Esophagus"},{"issue":"2","key":"3912_CR17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10388-022-00975-w","volume":"20","author":"S Aoyama","year":"2023","unstructured":"Aoyama S, et al. The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003. Esophagus. 2023;20(2):225\u201333.","journal-title":"Esophagus"},{"issue":"7","key":"3912_CR18","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/dote.12251","volume":"28","author":"B Mungo","year":"2015","unstructured":"Mungo B, et al. Does neoadjuvant therapy for esophageal cancer increase postoperative morbidity or mortality? Dis Esophagus. 2015;28(7):644\u201351.","journal-title":"Dis Esophagus"},{"issue":"17","key":"3912_CR19","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.2217\/fon-2021-0021","volume":"17","author":"J Han","year":"2021","unstructured":"Han J, Wang Z, Liu C. Survival and complications after neoadjuvant chemotherapy or chemoradiotherapy for esophageal cancer: a meta-analysis. Future Oncol. 2021;17(17):2257\u201374.","journal-title":"Future Oncol"},{"issue":"1","key":"3912_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41392-025-02254-3","volume":"10","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, et al. Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin\/cyclophosphamide for triple-negative breast cancer: a phase 2 TREND trial. Signal Transduct Target Ther. 2025;10(1):169.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3912_CR21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1186\/s12916-022-02696-4","volume":"20","author":"X Zhu","year":"2022","unstructured":"Zhu X, et al. Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial. BMC Med. 2022;20(1):493.","journal-title":"BMC Med"},{"issue":"1","key":"3912_CR22","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1186\/s12885-020-07282-6","volume":"20","author":"Q Wang","year":"2020","unstructured":"Wang Q, et al. Quantified MRI and 25OH-VitD3 can be used as effective biomarkers for patients with neoadjuvant chemotherapy-induced liver injury in CRCLM? BMC Cancer. 2020;20(1):767.","journal-title":"BMC Cancer"},{"issue":"8","key":"3912_CR23","doi-asserted-by":"publisher","first-page":"109646","DOI":"10.4251\/wjgo.v17.i8.109646","volume":"17","author":"YC Wang","year":"2025","unstructured":"Wang YC, et al. SOX plus sintilimab vs P-SOX vs SOX as neoadjuvant therapy in advanced gastric cancer: Efficacy and safety. World J Gastrointest Oncol. 2025;17(8):109646.","journal-title":"World J Gastrointest Oncol"},{"issue":"8","key":"3912_CR24","doi-asserted-by":"publisher","first-page":"e0271242","DOI":"10.1371\/journal.pone.0271242","volume":"17","author":"Y Guo","year":"2022","unstructured":"Guo Y, et al. Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for esophageal squamous cell cancer: A meta-analysis. PLoS ONE. 2022;17(8):e0271242.","journal-title":"PLoS ONE"},{"issue":"13","key":"3912_CR25","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1245\/s10434-019-07779-w","volume":"26","author":"BJ Noordman","year":"2019","unstructured":"Noordman BJ, et al. Quality of Life During and After Completion of Neoadjuvant Chemoradiotherapy for Esophageal and Junctional Cancer. Ann Surg Oncol. 2019;26(13):4765\u201372.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"3912_CR26","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/jso.24378","volume":"114","author":"N Haj Mohammad","year":"2016","unstructured":"Haj Mohammad N, et al. Activities of daily living and quality of life during treatment with neoadjuvant chemoradiotherapy and after surgery in patients with esophageal cancer. J Surg Oncol. 2016;114(6):684\u201390.","journal-title":"J Surg Oncol"},{"issue":"4","key":"3912_CR27","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1046\/j.1440-1746.2002.02728.x","volume":"17","author":"S Law","year":"2002","unstructured":"Law S, Wong J. Changing disease burden and management issues for esophageal cancer in the Asia-Pacific region. J Gastroenterol Hepatol. 2002;17(4):374\u201381.","journal-title":"J Gastroenterol Hepatol"},{"key":"3912_CR28","doi-asserted-by":"publisher","first-page":"103069","DOI":"10.1016\/j.critrevonc.2020.103069","volume":"154","author":"HG van den Boorn","year":"2020","unstructured":"van den Boorn HG, et al. Health-related quality of life in curatively-treated patients with esophageal or gastric cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020;154:103069.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3912_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12967-015-0579-9","volume":"13","author":"N Wang","year":"2015","unstructured":"Wang N, et al. The effect of socioeconomic status on health-care delay and treatment of esophageal cancer. J Transl Med. 2015;13:241.","journal-title":"J Transl Med"},{"issue":"2","key":"3912_CR30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1053\/j.semtcvs.2019.12.008","volume":"32","author":"S Asokan","year":"2020","unstructured":"Asokan S, et al. Presentation, Treatment, and Outcomes of Vulnerable Populations With Esophageal Cancer Treated at a Safety-Net Hospital. Semin Thorac Cardiovasc Surg. 2020;32(2):347\u201354.","journal-title":"Semin Thorac Cardiovasc Surg"},{"issue":"6","key":"3912_CR31","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1245\/s10434-021-11207-3","volume":"29","author":"X Gao","year":"2022","unstructured":"Gao X, et al. Neoadjuvant Therapy Versus Upfront Surgery for Patients With Clinical Stage 2 or 3 Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis. Ann Surg Oncol. 2022;29(6):3644\u201353.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"3912_CR32","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00259-017-3901-3","volume":"45","author":"WK Yap","year":"2018","unstructured":"Yap WK, et al. Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2018;45(5):689\u201398.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3912_CR33","doi-asserted-by":"crossref","unstructured":"Yap WK et al. Adjuvant Chemoradiotherapy Associated with Improved Overall Survival in Resected Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy in Intensity-Modulated Radiotherapy Era. Biomedicines, 2022. 10(11).","DOI":"10.3390\/biomedicines10112989"},{"issue":"8","key":"3912_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/dote\/dox021","volume":"30","author":"WK Yap","year":"2017","unstructured":"Yap WK, et al. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer. Dis Esophagus. 2017;30(8):1\u201310.","journal-title":"Dis Esophagus"},{"key":"3912_CR35","doi-asserted-by":"crossref","unstructured":"Lin CH et al. Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy. Cancers (Basel), 2020. 12(3).","DOI":"10.3390\/cancers12030607"},{"key":"3912_CR36","doi-asserted-by":"crossref","unstructured":"Yap WK et al. A Radiotherapy Dose Map-Guided Deep Learning Method for Predicting Pathological Complete Response in Esophageal Cancer Patients after Neoadjuvant Chemoradiotherapy Followed by Surgery. Biomedicines, 2023. 11(11).","DOI":"10.3390\/biomedicines11113072"},{"issue":"9","key":"3912_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/dote\/dox075","volume":"30","author":"A Okamura","year":"2017","unstructured":"Okamura A, et al. Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma. Dis Esophagus. 2017;30(9):1\u20138.","journal-title":"Dis Esophagus"},{"key":"3912_CR38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-2407-1-20","volume":"1","author":"JW Heise","year":"2001","unstructured":"Heise JW, et al. Expense and benefit of neoadjuvant treatment in squamous cell carcinoma of the esophagus. BMC Cancer. 2001;1:20.","journal-title":"BMC Cancer"}],"container-title":["Journal of Cardiothoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13019-026-03912-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-026-03912-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-026-03912-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T09:39:34Z","timestamp":1776332374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13019-026-03912-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3912"],"URL":"https:\/\/doi.org\/10.1186\/s13019-026-03912-5","relation":{},"ISSN":["1749-8090"],"issn-type":[{"value":"1749-8090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"16 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scheme of this report was approved by the Ethics Review Committee of the First Affiliated Hospital of Guangxi Medical University. Written informed consent was obtained from the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the participant for publication of identifying information\/images in an online open-access publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}